Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Blank, Christian U., Wong, Deborah J., Ho, Thai H., Bauer, Todd M., Lee, Carrie B., Bene-Tchaleu, Fabiola, Zhu, Jing, Zhang, Xiaosong, Cha, Edward, Sznol, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700717/
https://www.ncbi.nlm.nih.gov/pubmed/34940094
http://dx.doi.org/10.3390/curroncol28060455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700717/
https://www.ncbi.nlm.nih.gov/pubmed/34940094
http://dx.doi.org/10.3390/curroncol28060455

Ejemplares similares